PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PR Newswire•29/10/2026•16:01 ET
0
Key Highlights
- ➤Q3 total revenue $357.6M, up from $201.7M year over year
- ➤Sephience Q3 revenue $181.9M, up 20% from Q2 2026
- ➤2026 total revenue guidance raised to $1.29-$1.32B
- ➤2026 product revenue guidance raised to $960-$990M from $850-$950M
- ➤ST-920 acquired for $111M upfront, with up to $100M contingent milestones
Expert Statements
Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics
“We delivered another strong quarter of record product revenue led by the continued momentum of the Sephience launch, putting us firmly on track to achieve our cash flow breakeven milestone this year.”
Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics
“Now at the one-year mark, the launch has been a success by all measures. With a strong patient base, the large global market, and the reports of meaningful treatment benefits, we look forward to continued growth both in the US and internationally.”
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results PR Newswire
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue –
Get started
Create a free account to read the full story.